Pharmaceuticals, Volume 14, Issue 1 (January 2021) – 74 articles
Cover Story (view full-size image): COVID-19 pathogenesis is underscored by immune dysregulation which induces a cytokine storm that potentiates hyperinflammation and oxidative stress that can cause multi-organ damage and failure and, ultimately, death. Thus, therapeutic options that address this systemic dysfunction are critical. Severe cases of COVID-19 share similar pathogenic processes with multiple sclerosis and psoriasis, both of which are currently treated with dimethyl fumarate. Thus, we propose repurposing dimethyl fumarate, an immune-modulatory, anti-inflammatory, and anti-oxidative drug as a treatment option for severe cases of COVID-19. This perspective highlights the known effects of dimethyl fumarate and outlines the potential positive impact its clinical utilization could have for COVID-19. View this paper
- Issues are regarded as officially published after their release is announced to the table of contents alert mailing list.
- You may sign up for e-mail alerts to receive table of contents of newly released issues.
- PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.